UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 363.6	$ 645.5
Accounts receivable, net	485.4	472.7
Inventories	916.0	800.1
Assets held for sale	0.0	1.4
Other current assets	264.4	193.5
Total current assets	2,029.4	2,113.2
Property, plant and equipment, net	527.0	487.0
Goodwill	561.1	457.6
Intangible assets, net	291.9	270.9
Other long-term assets	410.2	283.1
Total assets	3,819.6	3,611.8
Current liabilities:
Current portion of long-term debt	121.0	18.7
Accounts payable	181.5	178.4
Deferred revenue and customer advances	381.2	370.2
Other current liabilities	388.6	347.0
Total current liabilities	1,072.3	914.3
Long-term debt	1,098.6	1,200.5
Other long-term liabilities	404.5	365.2
Commitments and contingencies (Note 16)
Redeemable noncontrolling interests	17.1	6.1
Shareholders' equity:
Preferred stock, $0.01 par value 5,000,000 shares authorized, none issued or outstanding	0.0	0.0
Common stock, $0.01 par value 260,000,000 shares authorized, 175,826,534 and 175,389,586 shares issued and 145,901,313 and 147,023,144 shares outstanding at September 30, 2023 and December 31, 2022, respectively.	1.7	1.7
Treasury stock, at cost, 29,925,221 and 28,366,442 shares at September 30, 2023 and December 31, 2022, respectively	(1,186.9)	(1,085.0)
Accumulated other comprehensive income (loss), net of tax	(5.2)	14.8
Other shareholders' equity	2,399.2	2,182.3
Total shareholders' equity attributable to Bruker Corporation	1,208.8	1,113.8
Noncontrolling interests in consolidated subsidiaries	18.3	11.9
Total shareholders' equity	1,227.1	1,125.7
Total liabilities, redeemable noncontrolling interests and shareholders' equity	$ 3,819.6	$ 3,611.8